Latham & Watkins Advises Eleusis, a Leading Medical Psychedelics Company, on the Acquisition of Kalypso Wellness Centers, a Provider of Infusion Therapies

A cross-border team advises the life sciences company on this transformative matter.

December 30, 2020

Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, has announced the launch of its clinical development of psychedelic infusion therapies and acquisition of Kalypso Wellness Centers, a leading provider of ketamine infusion therapies in the United States. Under the terms of the agreement, Eleusis acquired Kalypso and its intellectual property in an all-stock transaction. 

Latham & Watkins LLP represents Eleusis Ltd in the transaction with a deal team led by Boston/New York partner Kristen Grannis, Bay Area partner Haim Zaltzman, London partner Robbie McLaren and London associate Emily Cridland, with Boston associates Andrew Moosmann and Jeffrey Bashara. Advice was also provided on tax matters by New York partner Matthew Dewitz and London partner Karl Mah, with London associate James Leslie; on benefits and compensation matters by New York partner Austin Ozawa and London partner Sarah Gadd, with London associates Kendall Burnett, and Adam Ray and Chicago associate Dan Gocek; on intellectual property matters by Bay Area/San Diego partner Chris Hazuka, with Bay Area associate Katie Mladinich; and on regulatory matters by Washington D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang and Los Angeles counsel Jennifer Yoo.


 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.